Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence85
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma72
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma53
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma44
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?44
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review42
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review40
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence36
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects33
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events28
Current status and novel insights into the role of metastasectomy in the era of immunotherapy28
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis22
Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas20
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes19
Importance of radiation-related cognitive decline in older adults who receive cranial radiation19
Progress in histology specific treatments in soft tissue sarcoma18
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer17
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer17
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis17
1.3025498390198